Published • loading... • Updated
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Ant…
1 Articles
1 Articles
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Ant…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
